U.S. Geothermal Inc. (NYSEMKT:HTM) down by 6.07%, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)

Posted by Kristi Scott May 30, 2013 0 Comment 1621 views


Hartford, CT 05/30/2013 (GDPInsider) – U.S. Geothermal Inc. (NYSEMKT:HTM) closed its day at $0.399 after heading 6.07% downwards, dropping by $0.026. It opened its day at $0.42 after its previous day close of $0.43. The intraday range of the stock is $0.38 low and $0.42 high. The average volume of the stock over a period of 90 days is 494.099K. The market capitalization of the company is $43.14 million. The relative volume of the shares is 3.60. The beta of the stock which measures the volatility is 1.32. The target price of the stock is 0.62. The 52-weeks share price range for the stock is $0.26- $0.48. The current ratio 4.17, which is high, shows healthy liquidity and ability to deal with short-term debts.

U.S. Geothermal is currently engaged in green renewable business. The company is interested in three areas of United States which includes Neal Hot Springs area, Raft River area and areas of North Eastern Nevada.


Is HTM a solid investment at these levels?
Get valuable updates and exclusive insights here.

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) closed its day at $0.812 after heading 5.27% downwards, dropping by $0.045. It opened its day at $0.85 after its previous day close of $0.86. The intraday range of the stock is $0.81 low and $0.86 high. The average volume of the stock over a period of 90 days is 1.28 Million. With around 41.42 million outstanding shares, the market capitalization of the company is $33.64 million. The relative volume of the shares is 0.42. The beta of the stock which measures the volatility is 0.92. The target price of the stock is 2.25. The 52-weeks share price range for the stock is $0.37- $2.27. The current ratio 10.16, which is high, shows healthy liquidity and ability to deal with short-term debts.

There has been news about Catalyst Pharmaceutical that this bio pharmaceutical company is currently engaged in the development of drugs for rare neurological diseases.

How Should Investors Trade CPRX Now? Get key and important information right here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Kristi Scott

Kristi Scott joined GDP Insider in 2005 as a Wall Street reporter for the Business and Market section. Kristi covers the stock market, financial markets and personal finance. Her awards have come from the National Federation of Professional Writers, the Ohio Newspaper Association, the Cleveland Press Club, the Society of Professional Journalists and Suburban Newspapers of America. Kristi was named SNA's national Journalist of the Year

View all post by Kristi Scott Visit author's website

Write Your Comment